DexCom Toekomstige groei

Future criteriumcontroles 4/6

DexCom zal naar verwachting groeien in winst en omzet met respectievelijk 16.8% en 13.3% per jaar. De winst per aandeel zal naar verwachting groeien met 16.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 26.8% zijn.

Belangrijke informatie

16.8%

Groei van de winst

16.1%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	13.3%
Toekomstig rendement op eigen vermogen	26.8%
Dekking van analisten	Good
Laatst bijgewerkt	15 Nov 2024

Recente toekomstige groei-updates

Recent updates

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13

Winst- en omzetgroeiprognoses

NasdaqGS:DXCM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	5,312	953	1,001	1,378	21
12/31/2025	4,602	781	798	1,136	24
12/31/2024	4,016	634	603	937	24
9/30/2024	3,954	681	535	822	N/A
6/30/2024	3,935	667	666	891	N/A
3/31/2024	3,802	639	584	802	N/A
12/31/2023	3,622	542	512	749	N/A
9/30/2023	3,403	377	500	747	N/A
6/30/2023	3,198	358	466	771	N/A
3/31/2023	3,023	293	416	754	N/A
12/31/2022	2,910	341	305	670	N/A
9/30/2022	2,793	244	261	643	N/A
6/30/2022	2,673	230	216	597	N/A
3/31/2022	2,572	258	95	486	N/A
12/31/2021	2,449	217	53	443	N/A
9/30/2021	2,319	577	140	509	N/A
6/30/2021	2,170	562	101	409	N/A
3/31/2021	2,027	530	236	502	N/A
12/31/2020	1,927	550	277	476	N/A
9/30/2020	1,821	231	264	447	N/A
6/30/2020	1,716	205	209	394	N/A
3/31/2020	1,601	148	131	305	N/A
12/31/2019	1,476	101	135	315	N/A
9/30/2019	1,351	-171	51	205	N/A
6/30/2019	1,222	-170	39	167	N/A
3/31/2019	1,128	-130	53	144	N/A
12/31/2018	1,032	-127	56	123	N/A
9/30/2018	915	43	64	131	N/A
6/30/2018	833	-5	N/A	110	N/A
3/31/2018	761	-33	N/A	83	N/A
12/31/2017	719	-50	N/A	92	N/A
9/30/2017	669	-48	N/A	64	N/A
6/30/2017	633	-65	N/A	51	N/A
3/31/2017	599	-88	N/A	57	N/A
12/31/2016	573	-66	N/A	56	N/A
9/30/2016	533	-57	N/A	54	N/A
6/30/2016	490	-80	N/A	49	N/A
3/31/2016	445	-64	N/A	45	N/A
12/31/2015	402	-58	N/A	49	N/A
9/30/2015	356	-58	N/A	46	N/A
6/30/2015	319	-20	N/A	40	N/A
3/31/2015	285	-23	N/A	29	N/A
12/31/2014	259	-22	N/A	24	N/A
9/30/2014	227	-26	N/A	20	N/A
6/30/2014	201	-27	N/A	10	N/A
3/31/2014	178	-31	N/A	5	N/A
12/31/2013	160	-30	N/A	2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei DXCM ( 16.8% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van DXCM ( 16.8% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).

Hoge groeiwinsten: De winst van DXCM zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van DXCM ( 13.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van DXCM ( 13.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen DXCM zal naar verwachting over 3 jaar hoog zijn ( 26.8 %)

DexCom Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

DexCom, Inc. Updates Earnings Guidance for the Year 2024

DexCom, Inc. Provides Earnings Guidance for the Year 2024

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

Recent updates

Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

Third quarter 2024 earnings: EPS misses analyst expectations

DexCom Growing Into Its Valuation, But Still No Bargain

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships

Kessler Topaz Meltzer & Check, LLP Files Class Action Lawsuit Against Dexcom, Inc

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom: Investors Discounting Long CGM Growth Runway

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

DexCom, Inc. to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium

Stelo by Dexcom, the First Over-The-Counter Glucose Biosensor in the U.S., Is Now Available

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of DexCom, Inc

DexCom Q2 Earnings: Traditional Market Overreaction

Investor sentiment deteriorates as stock falls 37%

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 41% undervalued after recent price drop

Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

DexCom, Inc. Updates Earnings Guidance for the Year 2024

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $750 million worth of its shares.

Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

DexCom, Inc. to Report Q2, 2024 Results on Jul 25, 2024

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States

Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Now 22% overvalued after recent price rise

Dexcom: Positive Catalysts Ahead To Support Growth

If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

DexCom: Attractive Discount After Strong Earnings Results

DexCom, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

DexCom, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

DexCom, Inc., Annual General Meeting, May 22, 2024

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Now 24% overvalued after recent price rise

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Executive Chairman recently sold US$4.0m worth of stock

Executive Chairman notifies of intention to sell stock

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Executive VP notifies of intention to sell stock

DexCom: A Wealth Compounder In Healthcare

Full year 2023 earnings: EPS exceeds analyst expectations

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Executive Chairman recently sold US$4.6m worth of stock

DexCom: Stelo Stellar Outlook

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Insufficient new directors

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD